Acquisitions, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment - Research and Development and Collaborative Arrangements (Details) patient in Thousands	1 Months Ended						3 Months Ended	6 Months Ended
	May 31, 2016 USD ($)	Apr. 30, 2016 USD ($)	Jan. 31, 2016 USD ($)	Jul. 31, 2015 study patient	Mar. 31, 2015 USD ($)	Feb. 28, 2015 USD ($)	Jul. 03, 2016 USD ($)	Jul. 03, 2016 USD ($)
NovaQuest Co-Investment Fund II, L.P. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount	$ 250,000,000
Research and development arrangement, contingent payments, maximum	$ 195,000,000
Research and development arrangement, term	9 years
Research and development arrangement, percentage of costs to be reimbursed (up to)	40.00%
Funding to offset costs incurred under research and development arrangement							$ 69,300,000	$ 69,300,000
NovaQuest Co-Investment Fund V, L.P. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount		$ 200,000,000
Research and development arrangement, contingent payments, maximum		$ 267,000,000
Research and development arrangement, term		8 years
Research and development arrangement, percentage of costs to be reimbursed (up to)		100.00%
Funding to offset costs incurred under research and development arrangement							15,000,000	15,000,000
RPI Finance Trust [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount			$ 300,000,000
Research and development arrangement, contingent payments, maximum			$ 250,000,000
Research and development arrangement, term			7 years
Research and development arrangement, percentage of costs to be reimbursed (up to)			100.00%
Funding to offset costs incurred under research and development arrangement							$ 12,900,000	$ 21,700,000
Eli Lilly & Company (Lilly) [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of studies | study				6
Number of patients | patient				7
Eli Lilly & Company (Lilly) [Member] | Deferred Revenue [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received					$ 200,000,000
OPKO Health, Inc. [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments						$ 295,000,000
Contingent collaborative arrangement payments						$ 275,000,000